Clinical trials: Non-responders
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with…
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
- Trial name
- NCT00098475
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 138 sites in United States
- Volunteers
- 452 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab…
- Trial name
- NCT01332968
- Testing
- Obinutuzumab, Cyclophosphamide, Doxorubicin
- Where
- 183 sites in United States, Australia and 16 more
- Volunteers
- 1,401 people
- Sponsor
- Hoffmann-La Roche
Loss-of-control Eating, Obesity/Overweight
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery.
- Trial name
- NCT04599504
- Testing
- Lisdexamfetamine Dimesylate (Medication)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University
Oropharyngeal Neoplasms
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
This study looks at the use of three cycles of chemotherapy given prior to radiation therapy in patients with cancer of the oral cavity and evidence of prior exposure to Human Papilloma Virus (HPV).
- Trial name
- NCT01525927
- Testing
- chemotherapy, radiotherapy, Reduced dose radiotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwell Health
Obesity
BestFIT: a Personalized Weight Loss Program
The purpose of this study is to learn how to personalize weight loss programs. In this research we will study: 1. Whether a weight loss counselor should decide if the traditional weight loss therapy is working either after 3 or 7…
- Trial name
- NCT02368002
- Testing
- Behavioral weight loss therapy, Portion-controlled meals, Acceptance-based treatment
- Where
- United States
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Hepatitis C
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count.
- Trial name
- ENABLE-ALL (NCT00996216)
- Testing
- Eltrombopag, Antiviral therapy
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Diabetes
Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.
This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them…
- Trial name
- NCT04757519
- Testing
- DPP-GLB Standard, DPP-GLB Enhanced
- Where
- 21 sites in United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Lovoria Williams
Cirrhosis, Chronic Hepatitis C
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Background: Some people who have chronic hepatitis C do not respond to the usual treatment with peginterferon and ribavirin. New chronic hepatitis treatments are being developed that may work better for different people.
- Conditions
- Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT01888900
- Testing
- DUAL, QUAD
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Heart Failure
Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial
Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF) refractory to optimal medical management, in presence of a depressed left ventricular (LV) ejection fraction and a wide QRS complex.
- Trial name
- V3 (NCT01059175)
- Testing
- Additional Endocardial or Epicardial LV Lead, CRT-P or CRT-D
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Purpura, Thrombocytopenic, Idiopathic
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
- Trial name
- NCT02009761
- Testing
- BI 655064
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Boehringer Ingelheim
Obesity
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss.
- Trial name
- NCT03779048
- Testing
- Behavioral Treatment, Phentermine 15 MG
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Pennsylvania
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers.
- Trial name
- NCT00851006
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Utah
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
This observational study will assess the long-term efficacy and safety of MabThera/Rituxan in routine clinical practice in patients with sero-positive rheumatoid arthritis who are non-responders or intolerant to a single tumour…
- Trial name
- NCT01309282
- Where
- Portugal
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Heart Failure
Advance Cardiac Resynchronization Therapy (CRT) Registry
The intent of this registry is to understand comprehensive clinical care strategies for Cardiac Resynchronization Therapy (CRT) patients especially non-responders in real-world clinical practice.
- Trial name
- NCT01805154
- Testing
- CRT Patients
- Where
- 69 sites in United States, Argentina and 7 more
- Volunteers
- 1,529 people
- Sponsor
- Abbott Medical Devices
Hypertension
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood…
- Trial name
- BP CRUSH (NCT00791258)
- Testing
- amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
- Where
- 72 sites in United States
- Volunteers
- 999 people
- Sponsor
- Daiichi Sankyo
Heart Failure
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6…
- Trial name
- MORE CRT MPP (NCT02006069)
- Testing
- MPP
- Where
- 206 sites in United States, Australia and 28 more
- Volunteers
- 5,850 people
- Sponsor
- Abbott Medical Devices
Acute Migraine
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.
- Trial name
- NCT00894556
- Testing
- rizatriptan, Comparator: Sumatriptan
- Volunteers
- 109 people
- Sponsor
- Organon and Co